Lornoxicam

A simple, precise, and accurate UV spectrophotometric method was developed and validated for the simultaneous estimation of Lornoxicam and Thiocolchicoside in bulk and pharmaceutical formulations. The method employs methanol as solvent, and absorbance was measured at the respective wavelengths where both drugs showed maximum absorbance with minimal interference. Calibration curves were linear within the concentration ranges of 4–20 µg/mL for Lornoxicam and 5–25 µg/mL for Thiocolchicoside, with correlation coefficients (R²) of 0.9992 and 0.9995, respectively. Validation was carried out according to ICH Q2(R1) guidelines, including parameters such as linearity, accuracy, precision, LOD, LOQ, robustness, and ruggedness. Recovery studies at 50%, 100%, and 150% levels showed recoveries between 98.7–100.1%, indicating high accuracy. The proposed method is suitable for routine quality control of combined dosage forms of Lornoxicam and Thiocolchicoside.

The present research is focused on development of mouth dissolving tablet of Lornoxicam using novel superdisintegrants from natural resources. The research is carried out to potentiate the use of natural excipients instead of synthetic ones. Lornoxicam B cyclodextrin complex is formed as it increases the solubility of drug and to mask the taste of drug while having many advantages such as improve dissolution, and bioavailability. Tablets were prepared using natural superdisintegrants like gum karaya, Plantago ovata husk. and synthetic superdisintegrants like Crospovidone, Kyron T-314, Croscarmellose Sodium. Tablet containing 6 % of gum karaya shows better results over the formulation containing synthetic or other natural superdisintegrants like Plantago ovata husk. The formulated tablet melts in mouth within fraction of seconds with promising release of drug. The present study demonstrated potentials for rapid absorption, improved bioavailability, effective therapy, acceptable taste and patient compliance. The accelerated stability study of batch (F2) revealed that no significant change in physical properties and could be considered as stable formulation even after 3 months.

Lornoxicam is a non steroidal anti-inflammatory drug (NSAID) of the oxicam class. It belongs to BCS class II substance with low solubility and high permeability. The aim of current research is to formulate solid dispersion incorporated Fast disintegrating tablets of Lornoxicam to enhance the dissolution rate and aqueous solubility and to enable faster onset of action. Solid dispersions are prepared with polymers like Kolliwax GMS, Soluplus and HPMC in three different ratios 1:1:1, 1:2:1 and 1:3:1. Formulations were characterized for drug content studies, drug release studies and drug-polymer interactions using Fourier transform infrared spectroscopy (FTIR) spectrum. The solid dispersions can be evaluated by in-vitro dissolution studies. The optimized solid dispersion SD9 was further used to prepare fast disintegrating tablet by direct compression method using 33 Response surface method (3 variables and 3 levels of superdisintegrants) by using Design of experiment software with superdisintegrants like locust bean gum, gum karaya, Plant ago ovata. The values of pre-compression parameters evaluated were within prescribed limits that indicated good free flowing properties. The data obtained of post-compression parameters such as weight variation, hardness, friability, content uniformity, disintegration time (33 sec) and percentage drug release was maximum in LF24(99.21±1.87%) and was found to superior over conventional formulation. It can be concluded that fast disintegrating tablets using Lornoxicam solid dispersion could be used to improve better patient compliance in the effective management of pain and inflammation.

The aim of this work is to improve the anti-inflammatory activity of Lornoxicam through incorporating it in a topical gel using different polymers as Carbopol 934, Sodium carboxy methylcellulose or Sodium alginate. Various penetration enhancers (Glycerin, Polyethylene glycol or Sorbitol) were used with objective of enhancement in the percutaneous permeation of the drug. Formulations were evaluated for pH, drug content, rheological properties, spreadability, in-vitro drug release in phosphate buffer (pH 6.5) and permeation study through cellulose membrane. Anti-inflammatory activity of Lornoxicam gel was studied in rats by carrageenan induced paw edema method and compared with the commercial formulation (Feldene® gel). Considering physical properties, in-vitro release and in-vitro permeation studies, FS1 (Lornoxicam gel containing 1% Carbopol with 10% Sorbitol as penetration enhancer) was the best formula among the studied formulations, this formula also exhibited significantly higher anti-inflammatory activity in rats compared to Feldene® gel.

Lornoxicam is a non steroidal anti-inflammatory drug of oxicam class and it has the same side effects of this group when taken orally and has a relatively short plasma half-life (3 to 4 h) which makes it a good candidate for colon targeting. It could avoid the systemic side effects, enhance its low oral bioavailability due to hepatic first pass metabolism and delay drug release to target the colon. Eighteen tablet formulations of lornoxicam were prepared by wet granulation and coated with different polymers (pectin, chitosan, ethyl cellulose, cellulose acetate phthalate, eudragit L-100 and eudragit L-100-55), each at three concentration. The tablets were evaluated for their physical characters, in–vitro dissolution in gradient pH, as well as, mathematical modeling using DDSolver software package. The dissolution data best fitted to first order with Tlag model with Krosmyer Pepas (n) values around unity suggesting erosion mechanism for all tablets except pectin coated ones which showed Fickian diffusion mechanism. Fitting the release data to the different erosion models suggested heterogeneous erosion mechanism. Lornoxicam tablets coated with 6% Eudragit L-100 were successfully delivered to the colon with a relative bioavailability of 531.96% compared to the conventional commercial tablets in rabbits.

Osmotic systems use the principle of osmosis as delivery force to deliver the drug from the system, and the release rate is unaffected by the body’s pH and other physiological and gastrointestinal factors. Osmotic tablet of lornoxicam is prepared successfully to deliver drug in controlled release form for once day therapy in arthritis by overcoming all the side effect and enhancing bioavailability. The objective of the present work was to design osmotically driven oral drug delivery system containing Lornoxicam as an active ingredient and evaluate the effect of various membranes( microporous and semipermiable) on release of drug from osmotic tablet. Core tablet of lornoxicam is prepared, coated with cellulose acetate (39.8 D.S.) in which batch 6b (semipermiable) give the maximum of 91.04% release from osmotic tablet of lornoxicam in control passion as compare to other(microporous membrane coated batches.

Lornoxicam is comparatively a new non-steroidal anti-inflammatory drug, which is selective cyclooxygenase-1 and 2 (COX 1 and 2) inhibitors. Lornoxicam is a non steroidal anti-inflammatory drug that exhibits its anti inflammatory, analgesic and anti pyretic activities in animal models and it is presently available in the market only as tablet dosage form. It is preferred in the treatment of adults with osteoarthritis, acute pain rheumatoid arthritis, postoperative dental pain and primary dysmenorrhoea. The present study was undertaken with an intention to develop a stable and effective parenteral formulation, containing the drug Lornoxicam. Lornoxicam is a light sensitive and insoluble water soluble drug but unstable at higher temperature in water. So the effects of various co solvents in the solubility of  Lornoxicam have been evaluated. Lornoxicam was tried with co solvents such as PEG-400, β-cyclodextrin and Sodium Lauryl sulphate. The drug was made into injection formulation for administered as a SVP. Various batches of Lornoxicam injection formulation were prepared in order to assess the influence of heat, light, atmospheric oxygen and antioxidant on the stability of the drug and the formulations were also subjected to accelerated stability test. Out of all trials, formulation containing Sodium Lauryl sulphate was found to be more soluble, stable and passed all tests satisfactorily.